BRPI0610683B8 - aplicação colônica de absorventes - Google Patents

aplicação colônica de absorventes

Info

Publication number
BRPI0610683B8
BRPI0610683B8 BRPI0610683A BRPI0610683A BRPI0610683B8 BR PI0610683 B8 BRPI0610683 B8 BR PI0610683B8 BR PI0610683 A BRPI0610683 A BR PI0610683A BR PI0610683 A BRPI0610683 A BR PI0610683A BR PI0610683 B8 BRPI0610683 B8 BR PI0610683B8
Authority
BR
Brazil
Prior art keywords
colon
absorbent
absorbents
application
application systems
Prior art date
Application number
BRPI0610683A
Other languages
English (en)
Inventor
Andremont Antoine
Fattal Elias
Huguet Hélène-Céline
Tsapis Nicolas
Original Assignee
Hopitaux Paris Assist Publique
Centre Nat Rech Scient
Da Volterra
Univ Paris Diderot Paris 7
Univ Paris Sud 11
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hopitaux Paris Assist Publique, Centre Nat Rech Scient, Da Volterra, Univ Paris Diderot Paris 7, Univ Paris Sud 11 filed Critical Hopitaux Paris Assist Publique
Publication of BRPI0610683A2 publication Critical patent/BRPI0610683A2/pt
Publication of BRPI0610683B1 publication Critical patent/BRPI0610683B1/pt
Publication of BRPI0610683B8 publication Critical patent/BRPI0610683B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

aplicação colônica de absorventes. sistemas de aplicação em partículas, específicos de sítio (colônicos), oralmente administráveis, incluindo absorventes são revelados. quando aplicados especificamente ao colo, eles podem remover várias substâncias presentes no, ou conforme elas atingem o colo. métodos de tratamento usando os sistemas de aplicação, e métodos de preparação dos sistemas de aplicação, são também revelados. os sistemas de aplicação em partícula são baseados em matrizes absorventes encapsuladas em e/ou sobre partículas, que seletivamente liberam os absorventes para o colo. dispositivos de aplicação de fármaco representativos incluem contas de pectina, que podem ser opcionalmente ligadas com cruzamento com ions de metal tal como zinco e/ou cálcio. o sistema de aplicação protege o absorvente e previne seu efeito de absorção no trato gastrointestinal superior (g1). quando as partículas são feitas de pectina, e as contas são administradas ao colo, enzimas pectinolíticas específicas no colo degradam a pectina, permitindo que o absorvente seja liberado e seja completamente ativo. antibióticos, toxinas e outras substâncias absorvíveis presentes no colo será então inativados através de absorção no ou sobre o absorvente.
BRPI0610683A 2005-05-18 2006-05-18 aplicação colônica de absorventes BRPI0610683B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68207405P 2005-05-18 2005-05-18
US60/682,074 2005-05-18
PCT/EP2006/005629 WO2006122835A1 (en) 2005-05-18 2006-05-18 Colonic delivery of adsorbents

Publications (3)

Publication Number Publication Date
BRPI0610683A2 BRPI0610683A2 (pt) 2010-07-20
BRPI0610683B1 BRPI0610683B1 (pt) 2020-09-08
BRPI0610683B8 true BRPI0610683B8 (pt) 2021-05-25

Family

ID=36974012

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610683A BRPI0610683B8 (pt) 2005-05-18 2006-05-18 aplicação colônica de absorventes

Country Status (12)

Country Link
US (1) US8106000B2 (pt)
EP (1) EP1883396B1 (pt)
JP (1) JP2008540602A (pt)
CN (1) CN101257892B (pt)
AU (1) AU2006249100B2 (pt)
BR (1) BRPI0610683B8 (pt)
CA (1) CA2608505C (pt)
DK (1) DK1883396T3 (pt)
ES (1) ES2429095T3 (pt)
PL (1) PL1883396T3 (pt)
PT (1) PT1883396E (pt)
WO (1) WO2006122835A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US8932634B2 (en) * 2006-06-15 2015-01-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Hydrocolloid carrier beads with inert filler material
JP2010510196A (ja) * 2006-11-17 2010-04-02 ダ・ボルテラ オイドラギット被覆を施した亜鉛／ペクチンビーズを使用する結腸送達
US20080124279A1 (en) * 2006-11-17 2008-05-29 Antoine Andremont Colonic delivery using Zn/pectin beads with a Eudragit coating
US8273376B2 (en) 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
FI119678B (fi) * 2006-11-28 2009-02-13 Ipsat Therapies Oy Beta-laktamaasin käyttö
US20100239682A1 (en) * 2007-09-17 2010-09-23 Antoine Andremont Colonic delivery of antimicrobial agents
FR2950252B1 (fr) 2009-09-23 2012-01-20 Centre Nat Rech Scient Forme galenique capable d'adsorber de maniere specifique les molecules indesirables
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
KR101820374B1 (ko) 2010-02-23 2018-01-19 다 볼떼라 장 내 흡착제의 경구 전달을 위한 제형
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
RU2678124C2 (ru) 2014-04-17 2019-01-23 Синтесик Байолоджикс, Инк. Бета-лактамазы с улучшенными свойствами для лечения
CN106574273B (zh) 2014-08-28 2021-07-02 合成生物制品有限公司 β-内酰胺酶的基于大肠杆菌的生产
WO2016057744A1 (en) 2014-10-08 2016-04-14 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
EP3236993B1 (en) 2014-12-23 2023-09-13 Theriva Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
WO2016137993A1 (en) 2015-02-23 2016-09-01 Synthetic Biologics, Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
AU2016229976B2 (en) 2015-03-06 2021-11-11 Theriva Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
US20180303867A1 (en) * 2015-10-06 2018-10-25 Da Volterra Suppression or reduction of the pathogenicity or virulence of a clostridium bacteria
JP2021533150A (ja) 2018-08-05 2021-12-02 ダ・ヴォルテッラ 移植片対宿主病の治療のための組成物
BR112021002106A2 (pt) 2018-08-05 2021-06-01 Da Volterra método para aprimorar a eficácia de agente anticâncer
CN110051688B (zh) * 2019-05-07 2022-01-14 西北师范大学 半胱氨酸接枝凹凸棒石复合材料在制备解毒剂中的应用
CN111450049B (zh) * 2020-05-11 2021-06-25 中国药科大学 一种具有结肠特异性递送的微米水凝胶制备方法
WO2022084550A1 (en) 2020-10-23 2022-04-28 Da Volterra Compositions for use in the treatment or prevention of dysbiosis
WO2022090433A1 (en) 2020-10-30 2022-05-05 Da Volterra Method for the manufacture of an adsorbent formulation
WO2022101267A2 (en) 2020-11-12 2022-05-19 Da Volterra Compositions for delivery of an adsorbent
WO2022101269A1 (en) 2020-11-13 2022-05-19 Da Volterra Formulations and dosage regimen for oral delivery of adsorbents in the gut
CN112451541A (zh) * 2020-12-25 2021-03-09 刘长德 一种防治犬猫腹泻的组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2437878A1 (de) 1974-07-26 1976-02-12 Sandoz Ag Ueberzogene aktivkohleteilchen
JPH03120227A (ja) 1989-10-02 1991-05-22 Shigeo Ochi 飲食物消化分解産物吸収抑制剤
US5484773A (en) * 1994-02-14 1996-01-16 Alberta Research Council Treatment of antibiotic associated diarrhea
US5929051A (en) * 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins
CN100358509C (zh) 1998-09-28 2008-01-02 沃纳-兰伯特公司 采用hpmc胶囊进行肠和结肠传递
US6706287B2 (en) 2001-05-15 2004-03-16 Kibow Biotech Inc. Prebiotic and probiotic compositions and methods for their use in gut-based therapies
US6706263B2 (en) 1999-04-30 2004-03-16 Kibow Biotech Inc. Composition for alleviating symptoms of uremia in patients
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6991807B2 (en) 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
CN1326745A (zh) * 2000-06-01 2001-12-19 翟永功 蒙脱石为胃肠道药物的成份
US7105174B2 (en) 2000-10-13 2006-09-12 Advancis Pharmaceutical Corporation Multiple-delayed release anti-neoplastic product, use and formulation thereof
US7074417B2 (en) 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US7157095B2 (en) 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
EP1248599B1 (de) 2001-01-31 2007-12-05 Evonik Röhm GmbH Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
JP2002308786A (ja) * 2001-04-12 2002-10-23 Oto Corporation:Kk 食物繊維で包括されたカーボン粒入りゼリーの製造法
EP1435922A1 (de) 2001-10-15 2004-07-14 Röhm GmbH & Co. KG Verwendung eines copolymeren zur herstellung einer arzneiform, die als wirkstoff ein peptid oder protein enthält
WO2003086344A1 (en) 2001-12-20 2003-10-23 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2003075852A2 (en) 2002-03-07 2003-09-18 Advancis Pharmaceuticals Corporation Antibiotic composition
DE10214002A1 (de) 2002-03-27 2003-10-09 Roehm Gmbh Pharmazeutische Formulierung für den Wirkstoff Budesonid
US7317001B2 (en) 2002-06-06 2008-01-08 Oscient Pharmaceuticals Corporation Use of ramoplanin to treat diseases associated with the use of antibiotics
FR2843302B1 (fr) * 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
DE10250543A1 (de) 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
DE10260921A1 (de) 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Verfahren zum Überziehen von Substraten für pharmazeutische Anwendungen mit einem Gemisch aus zwei filmbildenden Überzugsmitteln
DE10332160A1 (de) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
AR045068A1 (es) 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
US20050244490A1 (en) 2003-12-09 2005-11-03 Michael Otto Dosing methods for beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
DK1566173T3 (da) 2004-02-20 2006-12-27 Mattern Udo Farmaceutisk sammensætning til oral anvendelse og fremgangsmåde til fremstilling deraf
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules

Also Published As

Publication number Publication date
CN101257892A (zh) 2008-09-03
WO2006122835A1 (en) 2006-11-23
BRPI0610683B1 (pt) 2020-09-08
AU2006249100B2 (en) 2012-01-19
WO2006122835B1 (en) 2007-04-12
US20090324568A1 (en) 2009-12-31
BRPI0610683A2 (pt) 2010-07-20
ES2429095T3 (es) 2013-11-13
EP1883396A1 (en) 2008-02-06
CN101257892B (zh) 2013-01-02
PT1883396E (pt) 2013-10-08
DK1883396T3 (da) 2013-10-07
US8106000B2 (en) 2012-01-31
CA2608505C (en) 2013-12-24
CA2608505A1 (en) 2006-11-23
JP2008540602A (ja) 2008-11-20
AU2006249100A1 (en) 2006-11-23
EP1883396B1 (en) 2013-07-03
PL1883396T3 (pl) 2014-03-31

Similar Documents

Publication Publication Date Title
BRPI0610683B8 (pt) aplicação colônica de absorventes
ES2441266T3 (es) Métodos para producir apósitos de herida húmedos antimicrobianos unidos a la plata y apósitos de herida húmedos producidos por dichos métodos
JP2016214906A5 (pt)
DE50307435D1 (de) Gegen missbrauch gesicherte darreichungsform
Cavallaro et al. Responsive and “smart” antibacterial surfaces: Common approaches and new developments
WO2006084912A8 (en) Device method, and use for treatment of neuropathy involving nitric oxide
WO2007073518A3 (en) Compounds and methods for thiol-containing compound efflux and cancer treatment
WO2008002657A3 (en) Microparticles containing active agent dispersed in a polymer matrix as implant or as coating for medical devices
TR200200562T2 (tr) Vücutta kontrollü şekilde salgılanabilen ve nahoş tadı önleyebilen ağızdan alınmaya mahsus farmasötik bileşimler
ATE396712T1 (de) Pharmazeutische zubereitung zur modifizierten freisetzung
CN103040727A (zh) 一种药物和蛋白质缓释海藻酸盐杂化凝胶的制备方法
WO2008073282A3 (en) Ph sensitive matrix formulation
WO2006039704A3 (en) Pharmaceutical composition and method for treating a joint capsule arthropathy
EP1834646A4 (en) ULTRASONIC CANCER THERAPY ACCELERATOR AND CYTOTOXIC AGENT
WO2014102613A3 (en) Device for disposal and neutralization of pharmaceutical agents
CN102091050A (zh) 一种稳定的辛伐他汀口服片剂及其制备方法
Rosu et al. Promising psyllium-based composite containing TiO2 nanoparticles as aspirin-carrier matrix
WO2004087212A3 (en) Nitric oxide in treatment of inflammation
WO2008153762A3 (en) S-nitrosothiol formulations and storage systems
NZ630040A (en) Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
WO2006138571A3 (en) Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance
CN205434422U (zh) 一种药物载体
WO2008147468A3 (en) Compositions comprising virus-interacting layered phyllosilicates and a therapeutic agent, and methods of use
WO2008068584A3 (en) A heterogeneously configured multiparticulate gastrointestinal drug delivery system
MX2022007977A (es) Formulacion plastica de liberacion prolongada.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: DA VOLTERRA (FR) , CENTRE NATIONAL DE LA RECHERCHE

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/05/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: DA VOLTERRA (FR) ; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; UNIVERSITE PARIS DIDEROT - PARIS 7 (FR) ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) ; UNIVERSITE PARIS-SACLAY (FR)

B25A Requested transfer of rights approved

Owner name: DA VOLTERRA (FR) ; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) ; UNIVERSITE PARIS-SACLAY (FR) ; UNIVERSITE DE PARIS (FR)

B25D Requested change of name of applicant approved

Owner name: DA VOLTERRA (FR) ; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) ; UNIVERSITE PARIS-SACLAY (FR) ; UNIVERSITE PARIS CITE (FR)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2775 DE 12-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.